FBXO5 and colorectal carcinoma: As heterozygous loss of EMI1 occurs in ~12% of all CRC patients and the above data support the possibility that reduced expression may be a pathogenic event, we next sought to assess the long-term impact EMI1 loss has on CIN in clinically relevant models.